# Diranersen / BIIB080 Phase 2

Source: https://onco.cc/trials/da-trial-biib080/  
OnCo record `da-trial-biib080` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Phase 2 study of BIIB080, an investigational tau-lowering antisense medicine.

## Summary

Intrathecal ASO programme. Safety and symptom outcomes are still being established. Trial-only access.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-21
- Tags: dementia-atlas
- Registry id: NCT05399888
- Phase: 2
- Setting: MCI due to AD or mild AD dementia
- Sponsor: Biogen

## Sources

- ClinicalTrials.gov NCT05399888: https://clinicaltrials.gov/study/NCT05399888

## Connected records

- diagnoses: [Alzheimer’s disease](https://onco.cc/diagnoses/alzheimers-disease/), [Mild cognitive impairment](https://onco.cc/diagnoses/mild-cognitive-impairment/)
- drugs: [Diranersen (BIIB080)](https://onco.cc/drugs/da-biib080/)
- companies: [Biogen](https://onco.cc/companies/da-biogen/)

---
JSON: https://onco.cc/api/v1/entities/da-trial-biib080.json